Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...
Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.
Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...
Metsera Inc. (MTSR), a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in existing ...
Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...
The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...
Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...
Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...
Learn more Cats can lose weight safely with one of the best weight loss foods for cats. These foods typically are lower in calories and fat and contain more nutrients per serving than other formulas.